Leap Therapeuticsincis A Clinical Stage Biopharmaceutical Company Based In Cambridgemassachusettsfounded In 2011The Company Focuses On Developing Targeted And Immuno Oncology Therapeutics For Various Cancersleap Therapeutics Is Publicly Traded On The Nasdaq Under The Ticker Symbol Lptx The Company S Pipeline Includes Several Promising Candidatessuch As Dkn 01Sirexatamab A Humanized Monoclonal Antibody Targeting The Dkk1 Protein For Treating Esophagogastricgynecologicand Colorectal Cancersother Candidates Include Fl 301Targeting Claudin18 2 For Gastric And Pancreatic Cancerfl 501Which Targets Gdf 15 And Is In Preclinical Developmentand Fl 302A Bispecific Antibody Targeting Both Claudin18 2 And Cd137Leap Therapeutics Has Established Partnerships With Adimabllc And Beigeneltdto Develop And Commercialize Dkn 01 In Select Regionsthe Leadership Team Comprises Experienced Professionalsincluding President & Ceo Douglas Onsi And Chief Medical Officer Cyndi Sirardmdthe Company Is Dedicated To Advancing Its Innovative Pipeline To Improve Cancer Treatment Options
No conferences found for this company.
| Company Name | Leap Therapeutics Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
